Identification of Neuroactive Constituents of the Ethyl Acetate Fraction from Cyperi Rhizoma Using Bioactivity-Guided Fractionation.
10.4062/biomolther.2016.091
- Author:
Yeomoon SIM
1
;
Jin Gyu CHOI
;
Pil Sung GU
;
Byeol RYU
;
Jeong Hee KIM
;
Insug KANG
;
Dae Sik JANG
;
Myung Sook OH
Author Information
1. Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02447, Republic of Korea. dsjang@khu.ac.kr
- Publication Type:Original Article
- Keywords:
Cyperi Rhizoma;
Scirpusin A;
Scirpusin B;
Neuroprotection;
Bioactivity-guided fractionation
- MeSH:
Cyperus;
In Vitro Techniques;
Luteolin;
Neurodegenerative Diseases;
Neurons;
Neuroprotection;
Neuroprotective Agents;
Rhizome
- From:Biomolecules & Therapeutics
2016;24(4):438-445
- CountryRepublic of Korea
- Language:English
-
Abstract:
Cyperi Rhizoma (CR), the rhizome of Cyperus rotundus L., exhibits neuroprotective effects in in vitro and in vivo models of neuronal diseases. Nevertheless, no study has aimed at finding the neuroactive constituent(s) of CR. In this study, we identified active compounds in a CR extract (CRE) using bioactivity-guided fractionation. We first compared the anti-oxidative and neuroprotective activities of four fractions and the CRE total extract. Only the ethyl acetate (EA) fraction revealed strong activity, and further isolation from the bioactive EA fraction yielded nine constituents: scirpusin A (1), scirpusin B (2), luteolin (3), 6′-acetyl-3,6-diferuloylsucrose (4), 4′,6′ diacetyl-3,6-diferuloylsucrose (5), p-coumaric acid (6), ferulic acid (7), pinellic acid (8), and fulgidic acid (9). The activities of constituents 1-9 were assessed in terms of anti-oxidative, neuroprotective, anti-inflammatory, and anti-amyloid-β activities. Constituents 1, 2, and 3 exhibited strong activities; constituents 1 and 2 were characterized for the first time in this study. These results provide evidence for the value of CRE as a source of multi-functional neuroprotectants, and constituents 1 and 2 may represent new candidates for further development in therapeutic use against neurodegenerative diseases.
